Earnings Call: Q2 2021

Jul 13, 2021

Ladies and gentlemen, welcome to the ex vivo group interim report Q2 2021. I will now hand over to Doug Anderson, CEO. Sir, please begin. Yes. Good morning, good afternoon, good evening, depending on where in the world you are right now, and welcome to the second Quarterly Telephone Conference 2021. I am happy to present with my CEO CFO, Christophe Nokstrom. And as mentioned in the quarterly reports, which was released this morning, we had a strong 2nd quarter from any aspects. Sales, margins and EBITDA showed very positive performance. Sales in local currencies increased by 116% in the quarter. Gross margin of non durable goods, 76% and EBITDA margin adjusted of 14%. These are very strong numbers. And on top of that, An organic growth of 82% for the thoracic business area, also worth mentioning since this is actually an exceptionally strong number. The level of recovery within organ transportation varies from country to country. In the U. S, the number of transplants increased for all major organs Compared with 2019, interesting to note regarding lung transplants It's a very strong second quarter number. During the Q2, 7 12 lung transplants We're performing in the U. S. Versus 675 in 2019 and 587 last year. In Europe, the recovery is slower and more fragmented. Central Europe recovering at a quicker pace. Nordic countries and Southern Europe at slower pace. This is, of course, strongly correlated with how much of the capacity there is In intensive care units for non COVID patients. As travel restrictions are now Or at least on their way to disappear, the commercial team within ex vivo is now able to meet with existing and Potential customers and discuss ENT programs, liver perfusion, kidney perfusion, etcetera. Consequently, we have also increased the number of customer training events and held very successful webinars on different topics such as Starting machine perfusion programs, kidney perfusion, etcetera. We have also continued to invest in our commercial team, as Earlier mentioned particular focus on preparing the U. S. Organization for the launch of the abdominal product range With initial focus on our highly acclaimed kidney assist transport, which was featured in the publication in Lancet November last year. We are also investing in Europe as we see reimbursement initiatives open up business opportunities in different countries. Coming back to Q2 highlights, It is worth mentioning the submission of the 510 application with FDA for the kidney disease transport, And we expect regulatory approval end of this quarter. NICE in the UK is supporting EVT, And we are actually starting an EVT program this quarter in a leading lung health center in United Kingdom. More clinics included in our European trials for heart preservation and also Primex. And we have started something very exciting, a Digital transformation journey, together with the University Medical Center in Groningen, one of the leading medical centers in the Netherlands. I will talk about these highlights in greater detail Arthur Christoffer has presented in the numbers. As regards financials, before I hand over to Christophe, I have already mentioned sales, Margins and EBITDA performance. Another important number is the machine perfusion percentage of net sales, Which in quarter 2 amounted to 52% versus 39% last year. This is very important, and it shows that customers are increasingly perfusing organs. And this is actually the only way to ensure that organs are in Optum and condition, ahead of the transportation. We had SEK 10,000,000 in onetime costs. 1 third of this month refers to an M and A process, which was terminated. So Christoper, you ready to talk through the numbers in greater detail? Yes. So thank you, Dag. Starting with a P and L overview and the key ratios. First of all, As you said, we are pleased with the overall net sales for the quarter, given the fact that there is still a COVID-nineteen effect on health care, especially in Europe. Net sales amounted to SEK 59,000,000 corresponding to growth of 95% compared to last year And 116% in local currencies. Overall, strong sales in America within lung transplantation compensated for weaker sales In Europe, for all organs, regarding gross margin, we are very pleased with the margins also for this quarter. Total gross margin, including both non durable goods and durable goods, was 75%. EBITDA adjusted for onetime costs was SEK 8,000,000 corresponding to an EBITDA margin of 14%. Same thing here. We are satisfied with this level, especially since we have invested quite a lot in the organization during the last 12 months here. And I will comment more on the onetime costs on my last slide here. Year to date, we present net sales of SEK 118,000,000 a total gross margin of 74% and an adjusted EBITDA margin of 12%. If we deep dive a bit into the thoracic business area, net sales amounted to EUR 50,000,000 Corresponding to a local currency growth of 82% was strong against 2020. And this was, as I said, mainly driven by a strong recovery in the U. S. On both Static preservation and machine perfusion, such as EDLP. Non durable goods accounted for 98% of sales. That means no XPF sales in this quarter. However, outlook is promising. And for example, we have increased our stock in the quarter to meet Future demand for our machines. In terms of regions, Americas accounted for 65% of sales, Europe 30% and APAC 5%. U. S. Strong, as we have said. For example, all our top 10 U. S. Clients are returning growth on year on year terms. And in terms of EVRP, the most important U. S. Clinics are now more or less returning to normal levels, which is very Satisfying. In Europe, the recovery varies country by country, and overall, it does not come as far as in the U. S. Gross margin on non durable goods was strong, 80% in the quarter, which is in line with last year. So next slide. If we look at the abdominal business area and the Q2 highlights, sales came in on SEK 9,000,000 Comparative figures in our report are missing since the acquisition took place in Q4 last year. However, organic growth For abdominal and former organ cyst was 126% compared to 2020, And sales came in line with the comparable quarter 2019. Year to date, 64% organic growth Compared to 2020, 56% organic growth compared to 2019. Non durable goods was 77% of sales and durable goods, meaning machines, was 23%. And as you know, abdominal more or less only operates in the Europe still. So 98% of sales He came from Europe. Gross margin, 52%, was in line with Q1. Let's move over to the EBITDA, perfect. And one back. One back. Exactly. So some comments on the EBITDA. Adjusted for onetime costs, EBITDA was €8,000,000 corresponding to a margin of 14%, as we said. The onetime costs, as we like to present them, amounted to SEK 10,000,000 in the quarter and consists of the following items: So cost of an M and A process. Costs from business integration with organ assist, we expect that type of cost to seize In the Q3. And finally, cost from cash based incentive programs for employees outside of Sweden. The rolling 12 months adjusted EBITDA is SEK 31,000,000 positive and also 14%. This could be compared with SEK 19,000,000 10% last year. Let's go to my final slide. Cash flow financial position. So the cash flow in the quarter, cash flow from operating activities was negative, minus SEK 13,000,000. Swedish krones and that was mainly due to our onetime costs of SEK 10,000,000. And furthermore, as I said, We increased our inventory during the quarter, which impacted on our cash flow. So both machines and disposable sets were manufactured in order to meet the future demand And to secure transition into new manufacturers. So except from big costs, based on strategic decisions, I would say that cash flow from our core business was Positive for the quarter. Cash flow from investing activities was minus SEK 23,000,000, Mainly attributable to investments in our R and D projects such as our heart preservation trials. And we ended on a cash position of SEK 311,000,000 in the end of Q2, and that is in line with our year to date expectations. Finally, we continue to have a healthy balance sheet, equity assets ratio of 88% and No external debt exists. And now I will hand over to you again, Doug. Thank you very much, Christoper, for this. I will then talk a little bit about Some of the significant events, which I already mentioned, but I will talk them through in more detail. If we start with one of the most important ones, the kidney assist transport. Nearly 2 thirds of all transplants in the world are kidney transplants. And therefore, our new kidney transplant will play an important role In preserving kidneys in optimal condition ahead of the transplant. An article published in the scientific journal The Lancet in November last year Truth that oxygenated perfusion of kidneys before transplantation has a significant impact on the 1st year results after transplantation. Less graft failure, better function and lower rejection of the kidney when compared to the cold perfusion alone. The plan to receive market clearance for the U. S. Launch by end Q3 is still valid, and U. S. Go to market strategy, pre launch activities, Education, supply chain optimization are all ongoing activities. We have already received questions on our filing from FDA, which is good, We are well prepared to provide them now with the answers. As mentioned earlier, we will Start an EVLT program in the UK during this quarter. One leading hospital will perform EVLT not only for the hospital itself, But also smaller lung transplant centers. This model is very exciting and a true breakthrough for us in the UK. And one important aim of this initiative is to collect EZFT data in order to support the reimbursement process in the U. K. As regards our clinical trials, notably the European Heart Preservation Study and PRIMIC, We are now including 5 centers in the heart rate in Europe, and we expect 3 more centers joining the study during the Q3. We have also decided to include additional centers in France and Germany to speed up the trial as much as possible And conclude the trial by end 2022 as earlier communicated. The same logic applies to Primek, Well, we intend to include the leading hospitals in Oslo and Copenhagen, and we are also in discussions with 2 leading German centers. I'm also very excited about the digital transformation journey we have initiated with the University Thank you, Groningen in advanced analytics. The project named Xcept aims at extracting liver perfusion data From our liver assist machine and the objective is to have surgeons make more data driven decisions And increase the number of successful limited transgons. We are also planning to initiate similar pilot project announced with the U. S. Transgons center in the near future. So what is key for us for the remainder of 2021? Well, We are in the process of preparing the 2022 to 2026 strategic plan, and we have a meeting with our leadership In Gothenburg, end August, to finalize the plan, we are we will become the global leader in machine perfusion for all major organs, And our strategy will tell us what we need to do to achieve this. Of course, the launch of the business is transport in the U. S. It's key to start our dominant journey in the U. S. We are also planning FDA submission for the liver assist Machine, we are, as I told you as well, speeding up PARP and PRIMIC trials And continue preparing for the launch of U. S. Products. We are also focusing on continued price increases in the U. S. And Europe And work with reimbursement authorities in Europe. So final comment, We will have our 1st Capital Markets Day on September 23 in GoCo Health Innovation sit in Gothenburg. There will also be an online webcast, of course, but we have a great agenda and hope to see as many of you there as possible. And as a company involved in preserving and evaluating organs, It is important never to forget the purpose of ex vivo, which is that we believe in an extended life of organs. Nobody should die waiting for a new order, and this is what I and my colleagues around the world strive for every single day. Wishing you all a great summer vacation. Thank you very much for listening. Thank you and goodbye. Thank you. And our first question comes from Tratnoff from Carnegie. Please go ahead. Your line is now open. Thank you very much, and good afternoon, both Doug and Christoffer. And I'll start off with just a strong development in the thoracic segment and Essentially for Lungs, I see a non durable sales up 75% year over year. Putting that into context of the increased number of transplantation, And I'm not sure if I got this right, but it was it up 21% year over year, 7 12 versus €587,000,000 last year? And if so, are you gaining market share? Or is this just purely And effect of your price increases. No, I mean, as you remember the number correct, I mean, it was SEK 5.87 In quarter 2 last year, it was €675,000,000 in 2019 and €712,000,000 this year. We I believe that we are actually gaining some market share as well in the U. S. I mean, if we look at the large customers we have, We are doing more land transplants with those customers than ever before. So It's a combination of gaining market share. It's also a combination of course, price increase plays a role here as well. And the gender is sort of Market growth. So you have the organic growth, you have gains market share and you have price increases, which all lead to this fantastic development. And if you could help shed some light on the price increases. So how much are we now currently on sort of year on year basis for both. Yes. No, but we made a price increase in Q4 Last year, 15% in U. S. On warm perfusion and 10% on cold. And we have been There have been really not been any objections from the customers here. So I would say that we have had a full impact of that Of those increases on the thoracic sales in the U. S. Perfect. Thanks. And on to the gross margin. And as for the abdominal segment, noted that it was affected by change in supplier. Yes. If you could help us with just how much that was in Q2. And you mentioned that will not be a sort of any major effect Into Q3 as well as will the new supplier provide you with sort of cheaper options that would have positive effects on this nondurable goods for the abdominal segment. Do you want to answer that? Exactly. So there is we are in the middle of a transition to new suppliers. In that process with the old supplier, We have received higher prices on the present kits that we sell, and we need to live with that For a couple of months here, the new kits that will be manufactured will have a lower A bit lower manufacturing price, which is good. But as you can see, the gross margin was More or less in line with Q1. And that has also to do with the fact that the amount of distributor sales In Q2 was lower than in Q1. So there we had a positive effect isolated to this quarter that Offset the higher prices, I would say, on the kits on the purchasing prices. Okay. Now we look in the future, we believe that I mean and the target, I mean, For European sales, until we go over to the new kits, the level of gross margin that we present now It's reasonable, so to say. A U. S. Launch, of course, will give us possibilities to increase that margin. Perfect. And just on the one off costs in the quarter, obviously, interesting to see that The M and A activity remained high, and I'm guessing you won't go into detail on what type of acquisition that was related to. But if you were to focus on the one off related to the cash based incentive programs, when will that start to abate? And will are we to expect or similar effects going into Q3 and Q4? Thank you. I totally understand the question because it is a onetime cost that is a bit odd since it has nothing to do with our operations and It is only an effect of the increase or decrease of our share price. So the history is that We have historically launched incentive programs such as subscription warrants for Swedish employees, We have not offered that to our employees outside of Sweden and instead we have offered them a bonus model that more or less mirrors this potential out So we there will not be a cash effect in future Quarters until potentially the Q2 in next year because we have these 2 year programs that are running. So there's one program left with this associated with this type of cost, An incentive program that ends in May 2022. Then potentially, there will be a cash effect, But all quarters until May 2022 could have a P and L effect based on the share price development. Okay. Fully understood. And then on to exciting times ahead for the abdominal segment. Obviously, it looks like the kidney transport device is ready to be launched on the U. S. Market fairly soon. But what about Liberasys? What is left before filing for U. S. Approval for that Product as well as, if I remember correctly, there were earnouts related to the acquisition of Organisys, Related to these some milestones, are these earn outs where we are to expect To be paid out during the next 6 months? I mean to answer the last question first, I mean, of course, I would like to see the earn out Paid earn out, paid out because that also shows things are being delivered. And then there are 2 components in the earn out. 1 is the kidney assist transport Registration completed by end 2021, and the other component is The sales value of the dominant product range globally in 2021. And as it looks now, The way we plan things, we are they expect or it's expected that the earn out will it will be paid out. So That's where we are right now, but it is also very much linked to the timing of the launch of Kinesid Transport because So part of the budget for the abdominal range is linked to U. S. Sales in the Q4 of this year of Kidney Assist Transport. So hopefully, if everything moves forward the way it's doing now and we get the FDA registration completed by the end of September and we can launch the So selling in October, then of course, we should it should sort of be fine. So that's on earnout and kidney. Working out to liver, We are in the process of filing for the registration FDA registration. The challenge we delivered Sysd is that There isn't really a similar machine on the market. So we are trying to see here also what Categories we've folded under, and there is something called the Novo category, which we hope would be the case with liver system. And So we are in the process of communicating with FDA and trying to assess what kind of registration Process is the correct one for this device. I mean the work has started, and we expect to have it done By next year, but the big focus now is, of course, the business is transport. We have to sort of focus and do things Also one at the times, we can't just do everything simultaneously. So there's nothing in the budget for this year Related to liver assist in the U. S, it's only sold in Europe. And then we'll see how we Plan and value for 2022. Did that answer your question? Yes, perfect. Thank you, Doug. Two last questions on my side before I'll get back into the queue. NICE and obviously sort of the track towards reimbursement in the U. K. Is Interesting. And you mentioned that you're expecting reimbursement to be in place in Q1 2023, but what are we to Back in terms of costs, it's To be seen like for reimbursement in the U. K. Up until 2023, will there be any sort of cost coverage from NICE during that point in time? Yes, yes. I mean, we are going to we will sell in quarter 3. We will start selling to 1 very large center in the UK who also will work With Magnus from Aberystenters. So we are in the process to prove our case. NICE has given us this What we call it, Christoper, it's like a temporary financing of EVMT Also for us to be able to prove our case so that it counts nationwide reimbursement, but we expect Good sales and it is based in the center during quarter 3. So that's already decided. So we will start selling officially in the UK this quarter. And is there any sort of So more reimbursement for the UK. Sorry. So what is the current limitation from a budget perspective for EVA LP and under the NICE sort of Agreement that you currently have. I don't know exactly how the agreement is formulated, but we know that we will be there is a certain quantity of The reality that will be performed, which we are which we have already discussed. The negotiated price is already decided. So everything is ready, but it's not a full national reimbursement yet. It's a selected reimbursement because there is Great belief in EVFT. And we are starting to sell in the U. K. As if there was reimbursement, but only for this Center with some smaller centers attached to this very big center in the UK. I don't really have more details than that right now, but So we see sales doing 43 in the UK, yes. Okay, perfect. And just last question, and I don't Want to sort of infringe on the Capital Markets Day, where I'm guessing you will talk more about this. But if you can give us some more insight on to The digital efforts that you're currently doing and the press release from last week, what that entails in terms of How that would imply in terms of adoption of both in the abdominal and traffic segments As well as is this a new segment where you're seeing transplantation moving towards? I mean, there are many Reasons to work with digital Transformation in the area of lung and liver and also kidney and heart transplantation. And We are starting this initiative in Netherlands. We are also starting in the U. S. We are not allowed yet to mention the sites for legal reasons, But we believe that there is a lot to be done when it comes to algorithm risk in terms of predicting The functionality and suitability of organs, and we will talk much more about that At the Capital Markets Day. So I would if you don't mind, I would prefer not to say more than this right now. Since September, we would be able also To reveal the U. S. Center and what we expect to get out of it. So would it be fine if I didn't go through this Talking through in more detail right now? That is perfect. We'll have something to look forward to at the Capital Markets Day. Absolutely. Perfect. Thank you very much, both Doug and Christophe, and I'll go back into the queue, and congratulation on a great quarter. Thank you for very good questions. Thank you. Our next question comes from Dylan Van Harstien from Royal and Garnier and Co. Please go ahead. Hi, Doug, Christopher. I hope you're well. Thanks for taking my questions and congrats on a nice print. Perhaps unsurprisingly, most of my questions have been answered. But just 2, I understand you might not be able to exactly give me a range, but could you give me Sort of a rough estimate of the transplant capacity versus last year for U. S. And Europe. I know U. S. Is ahead of last year, nothing As disrupted, but in Europe, I understand it can be very wide, but anything here helps. And my second question would be, I also noticed you Had some more capital spending or it appears this way at least on the side of the spenders buying more machines. Could you perhaps tell me a bit about the placements and what kind of devices you placed? And if this is a leading indicator for nondurable sales Q3, what kind of range do you expect that to be relevant? Thank you. Thank you, Dylan, and good to hear From you as well. I mean, when it comes to Europe, I mean, it is very much varying From country to country, I mean, there are certain countries which are relatively strong. I mean Benelux, for example, is performing relatively well. So with Austria and Switzerland, whereas Scandinavia and Spain has You've really not been able to do, for example, anything on the EVFG side Due to the COVID situation, I think Germany, where we don't really have reimbursement yet for lungs, I mean, Germany is also a country where Intensive care capacity has been relatively high, and they have also managed the COVID-nineteen situation much better and been able to Form other surgeries, including sort of organ transplantation. But it's hard to give you exact Percentages. I don't know, Christophe, if we have anything to share, which gives precise Presentation of the call back to 2019, 'twenty. Yes. No, but as you said, and it is tied to both the Domino area and the thoracic is that, for example, Southern Europe has so far been a struggle And has the impact on our sales, Italy, Spain, France, for example. In relation to thoracic, what we see is that, for example, the EVLP programs I've not seen such a significant recovery as we see in the U. S. So I think that is the main difference between when it comes to lungs Between the two continents. And I didn't really could you please Rephrase your second question. Sure. So just on I saw that durable sales are actually going well. I was just wondering what kind of devices you placed and if they're placed in new centers and if these are all EVLP devices or other devices. So durable sales in the quarter was if we talk about excess machines in lung We're here actually, no sales and no placements. But the outlook is good. We're having interesting discussions with centers in That's new centers in both U. S. And Europe, which is good. When it comes to abdominal, we are looking at different possibilities. If we should sell machines, if we should Plate machines with a volume commitment, that is an ongoing process at the moment. But for Lance, normally, when Yes. And for Langs, we have we know that there should have been some probably 1 or 2 deliveries in Q2 that will now happen in Q3 instead. So we have we know relative to customers in the U. S. Who will take Keurla machine. We have U. K. We So probably 2 more machines in Europe coming in quarter 3, early quarter 4. So quarter 2021 could actually be The strongest year ever for XDF machines if everything goes according to plan. Excellent. Thank you very much for taking my questions. Thank you, David. Thank you. Our next question comes from Ivan Ioannis from Red Army. Congratulations also It's only the quarter, but I understand a pretty good outlook as well. But yes, Few things. UK prices, you have offset, and I guess you won't Release any prices this way, but is there anything we can say about the price level that That's been said. You mean for the UK? Yes, indeed. Yes. I mean, I don't have the exact price, but I know it's a good price. That's all I know I haven't seen the exact price level in pounds. I don't know Christoph, if you have seen it, but it has been agreed. It's a good price level. I mean, definitely not where I mean, Europe average or above, I mean, a good price. That's all I know. That's helpful. And is there anything that could be said about You were pretty specific that we should expect Q3 sales already from the UK. Is there anything we can Say about the volumes that say it's a big sensor, there was some satellite or related Yes, I mean We are not allowed yet to reveal the customer as I understand it. But it's a very famous and big hospital, and I'm sure you could guess which one it is. And there will be 2 smaller hospitals that will also You use this big sensor and the XPF machine for DVMT. I don't want to give any Number when it comes to how many EBITDs will be performed, but it is a Good number. That makes us my commercial team is happy. And if they are happy, it means that it is a good number. So We will be able to say more after Q3 and maybe even at the Capital Markets Day. But I would prefer not to Say anything that makes this sensitive because we are just sort of about to start up with this program in the UK. That's understandable. And also, you seem to be pretty confident about the U. S. Launch, possibly already in October, and that's also related to some earn out. Is that Is there anything to be said about these volumes? No, I mean we have planned a certain budget For the U. S. For the Q4, we are planning to sell A certain number of keyless assist transport, it's we have already We are already talking to the centers. We are prioritizing the centers because we believe this will be in high demand. But of course, When you launch something, you have to be a little bit careful in the beginning because you will always have a buildup of the stock and supply and so on. And so We are talking about a good number. We are not able to talk about the exact number when it comes to the U. S. Because it's in the future, but for the Gerdome product range, this number is significant, and It's a good margin and so on. So once again, I mean, unfortunately, I will have to pause here. And then When things happen, we will be able to talk about it again. Thank you. So you are pretty confident That amount will come into play. Yes. I mean, I am confident. I mean, we are working According to the plan that we communicated since a long time, we have FDA registration and commercial launch. Then of course, something can always happen last minute, you never know. But I mean, we are working with this. We have great project team. People are Making sure that things are being delivered according to the timetable that has been established, and we have appointed A product champion for the U. S. We have appointed a marketing manager for the U. S. So many things are in place for this Launch, we are just sort of waiting for the formal FDA approval. And once we get that, We can start shipping the device to the U. S, absolutely. Thank you. That's all from me. Thank you. And our next question comes from Caroline Daniel from Danske Bank. Please go ahead. Your line is now open. Hi, Doug. Hi, Christopher. Thanks for taking my questions, which unsurprisingly, most Have been answered already. However, I was wondering if you could shed some light on where you see the long term gross margins Going for nondurable goods, obviously, a bit lower due to abdominal being part of it since Q4. So once you see price adjustments and so on in place, where do you see gross margins ending up overall Christophe, do you want to take this, please? Yes, sure. When it comes to abdominal, There is a lot to do on the margin, and we will take this step by step. We have experience from our non durable goods in lung, lung transplantation, We should reach something similar. However, we should know that at the moment, we have a highly profitable solution, the Perftex for non gerbicotin lung, which we don't have for abdominal. But Excluding that, I would say that our midterm goal here would be around 70%, should be reasonable for the abdominal On disposables, we will work with the price increases. But for other industries, of course, there will also There will be increases on the other end as well, MDR costs and raw But I mean U. S. Price levels are generally higher than European price So the more we sell in the U. S, the better for the gross margin. So I think 70% is a good benchmark for the abdominal For the disposable products. Yes. Does that also answer your question? Oh, for sure. Yes. Thank you. So most questions have been answered already. So I'm kind of stuck with more of a sentiment kind of question. So you're not getting much pushback on your price adjustments. And I know as you said, Doug, prices are We're hiring in the U. S. Would you say that the sentiment is the same when You raised your prices in U. S. Versus Europe or I mean the big difference is, of course, If you have reimbursement in a country, if you have good reimbursement, then of course it's much easier to talk about price increases. And if you look at U. S. As example, if you take one competitor like TransMedics, who is pricing Much, much higher than we are, and they have an inferior product to us. So in the U. S, there is competition who is paid with very high price. And that makes it, of course, easier for us to raise our prices. In Europe, it varies from country Depending on whether what kind of reimbursement model is in place, in Europe, we also have Certain contracts which have been long contracts with limited price increase opportunities, but we are increasing prices in Europe wherever we can, and we will To do so, but it's easier to do it in the U. S. Because of the reimbursement model in Sure. Sure. Understood. All right. That's all from me. Congrats On a good and stable quarter, guys. Thank you, Carla. Thank you. Thanks. Thank you. And as there appear to be no more audio you all for listening and welcome hopefully some of you to the Capital Markets Day and for everyone else, we'll be in touch